跳轉至內容
Merck
全部照片(1)

重要文件

查看所有文件

SML1854

Sigma-Aldrich

巴诺蒽醌 二盐酸盐

≥98% (HPLC)

同義詞:

1,4-双[[[2-（二甲基氧化氨基）乙基]氨基] -5,8-二羟基-9,10-蒽二酮, AQ4N 二盐酸盐

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C22H28N4O6 · 2HCl
CAS號碼:
252979-56-9
分子量：:
517.40
MDL號碼:
MFCD19690955
分類程式碼代碼:
12352200
NACRES:
NA.77

品質等級

100

化驗

≥98% (HPLC)

形狀

powder

儲存條件

desiccated

顏色

blue

溶解度

H2O: 3 mg/mL, clear (warmed)

儲存溫度

2-8°C

SMILES 字串

O=C1C2=C(C(NCC[N+](C)([O-])C)=CC=C2NCC[N+]([O-])(C)C)C(C3=C(O)C=CC(O)=C31)=O.[H]Cl.[H]Cl

InChI

1S/C22H28N4O6.2ClH/c1-25(2,31)11-9-23-13-5-6-14(24-10-12-26(3,4)32)18-17(13)21(29)19-15(27)7-8-16(28)20(19)22(18)30;;/h5-8,23-24,27-28H,9-12H2,1-4H3;2*1H

InChI 密鑰

SBWCPHUXRZRTDP-UHFFFAOYSA-N

應用

Banoxantrone Dihydrochloride作为有机配体用于自组装金属-有机配位纳米粒子(Cu–OCNP/Lap)的合成。它也被用于制备超分子功能化氧化石墨烯，用于癌症的缺氧活化化疗。

生化／生理作用

Banoxantrone Dihydrochloride可增强辐射所致的抗肿瘤作用。
巴诺蒽醌（AQ4N）是拓扑异构酶II抑制剂AQ4（生物还原性AQ4前体）的一种低氧激活前药。

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Olivier Trédan et al.
Cancer research, 69(3), 940-947 (2009-01-30)
Hypoxic tumor cells are likely to be resistant to conventional chemotherapy, in large part because many anticancer drugs are unable to penetrate into poorly oxygenated tumor tissue. Here, we used quantitative immunofluorescence to study the distribution of mitoxantrone and AQ4N
Alshad S Lalani et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 13(7), 2216-2225 (2007-04-04)
The antitumor activities and pharmacokinetics of the hypoxia-activated cytotoxin AQ4N and its metabolites were assessed in several preclinical models of pancreatic cancers. The cytotoxic effects of AQ4N prodrug and its bioreduced form, AQ4, were tested against multiple human tumor cell
Heather Nesbitt et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 23(7), 1797-1808 (2016-10-05)
Purpose: To understand the role of hypoxia in prostate tumor progression and to evaluate the ability of the novel unidirectional hypoxia-activated prodrug OCT1002 to enhance the antitumor effect of bicalutamide.Experimental Design: The effect of OCT1002 on prostate cancer cells (LNCaP
O P Friery et al.
British journal of cancer, 82(8), 1469-1473 (2000-04-26)
The ability of the bioreductive drugs AQ4N and tirapazamine to enhance the anti-tumour effect of cyclophosphamide was assessed in three murine tumour models. In male BDF mice implanted with the T50/80 mammary carcinoma, AQ4N (50-150 mg kg(-1)) in combination with

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務